Methods for treating bone loss with antibodies to OPGL
First Claim
Patent Images
1. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO:
- 13 and the light chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO;
14, wherein the heavy chain and light chain form an antibody that interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).
1 Assignment
0 Petitions
Accused Products
Abstract
Antibodies that interact with osteoprotegerin ligand (OPGL) are described. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are described. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are described.
37 Citations
36 Claims
-
1. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO:
- 13 and the light chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO;
14, wherein the heavy chain and light chain form an antibody that interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR). - View Dependent Claims (2, 3, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)
- 13 and the light chain comprises CDR1, CDR2, and CDR3 of SEQ ID NO;
-
4. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the heavy chain comprises the amino acid sequence as set forth in SEQ ID NO:
- 13, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).
- View Dependent Claims (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)
-
16. A method of treating bone loss in a patient, comprising administering an antibody comprising a heavy chain and a light chain, wherein the light chain comprises the amino acid sequence as set forth in SEQ ID NO:
- 14, wherein an antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).
- View Dependent Claims (17, 18)
-
19. A method of treating bone loss in a patient, comprising administering an antibody produced by a method comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO:
- 13 and the second polynucleotide encodes a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO;
14, and wherein the antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).
- 13 and the second polynucleotide encodes a light chain comprising CDR1, CDR2, and CDR3 of SEQ ID NO;
-
20. A method of treating bone loss in a patient, comprising administering an antibody produced by a method comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence set forth in SEQ ID NO:
- 13 and the second polynucleotide encodes a light chain, and wherein the antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).
- View Dependent Claims (23)
-
21. A method of treating bone loss in a patient, comprising administering an antibody produced by a method comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain and the second polynucleotide encodes a light chain comprising the amino acid sequence of SEQ ID NO:
- 14, and wherein the antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).
-
22. A method of treating bone loss in a patient, comprising administering an antibody produced by a method comprising expressing a first polynucleotide and a second polynucleotide in an isolated host cell, wherein the first polynucleotide encodes a heavy chain comprising the amino acid sequence of SEQ ID NO:
- 2 and the second polynucleotide encodes a light chain comprising the amino acid sequence of SEQ ID NO;
4, and wherein the antibody comprising the heavy chain and the light chain interacts with a human osteoprotegerin ligand (OPGL) and inhibits binding of human OPGL to an osteoclast differentiation and activation receptor (ODAR).
- 2 and the second polynucleotide encodes a light chain comprising the amino acid sequence of SEQ ID NO;
Specification